Daily close, T-120 (10/9/24) through T+5. Run-up high $39.16 on 3/10/25, low $25.39 on 10/16/24 (T-120 to T-1). FDA decision 3/26/25. Historical price action, not a forecast.
Positioning before the decision
On Mar 12, 2025, 14 days before the decision date, at-the-money options priced a move of ±10.4% through Apr 17, 2025 (the first listed expiry after the decision; ATM implied volatility 41%). The stock closed -1.9% at the first close across the decision and -3.5% five trading days on. A straddle priced weeks out covers ordinary movement plus the event, so this is the move the options market priced through that expiry, not the event-implied move alone. How this compares across 1,000+ decisions.
Was CABOMETYX (cabozantinib) - (CABINET) approved by the FDA?
Yes. The FDA approved the application for CABOMETYX (cabozantinib) - (CABINET) on March 26, 2025. The primary source is linked on this page.
What was CABOMETYX (cabozantinib) - (CABINET) under FDA review for?
The application covered Advanced Neuroendocrine Tumors. The FDA approved the application on March 26, 2025.
How did EXEL stock react to the FDA decision?
On the decision day EXEL moved -1.9%. That is the recorded reaction to this specific event -- historical measurement, not a prediction, and not investment advice.